By Delilah Alvarado
Published July 17, 2026
In a high-stakes maneuver designed to stave off insolvency and revitalize its clinical prospects, Jasper Therapeutics announced on Thursday that it has completed an all-stock acquisition of Kira Pharmaceuticals. The deal, which includes a concurrent $132 million private stock offering, provides the cash-strapped biotech with the necessary capital to extend its operational runway through the second half of 2028.
For Jasper, the merger is more than a financial arrangement; it is a fundamental pivot. The company, which had reported a precarious cash balance of just $14 million at the end of the first quarter of 2026, had spent the better part of the last year grappling with clinical setbacks that decimated its market capitalization. By integrating Kira’s pipeline of complement-system inhibitors, Jasper aims to transition from a single-asset-dependent firm into a diversified player in the competitive field of immunology.
The Strategic Shift: A Response to Clinical Turbulence
The necessity for this merger was born out of a series of operational and clinical hurdles that plagued Jasper throughout 2025. The company’s primary focus had been the development of briquilimab, an experimental treatment for chronic spontaneous urticaria (CSU), a form of debilitating chronic hives. However, momentum shifted sharply downward in mid-2025 when a manufacturing discrepancy involving a faulty batch of the drug product compromised the results of a critical clinical trial.
The fallout was swift. The data, rendered difficult to interpret, forced the company to undergo a brutal corporate restructuring. Jasper laid off approximately 50% of its workforce, halted several secondary research programs, and saw the departure of its chief medical officer. The "strategic alternatives" process initiated last month was the final acknowledgment that the company could not continue on its current trajectory without a significant infusion of capital or a new strategic direction.
Chronology of the Transformation
The path to the Kira acquisition marks the conclusion of a tumultuous 18-month period for the San Francisco-based biotech.
- Q2 2025: Jasper reports a clinical data update for briquilimab in CSU; however, findings are clouded by a "faulty batch" issue in the trial supply, triggering internal reviews and investor concern.
- Late 2025: Faced with dwindling cash reserves, Jasper executes a major corporate reorganization, cutting staff and pausing non-core research.
- June 2026: Jasper officially announces it is seeking "strategic alternatives," signaling to the market that a merger or sale is imminent.
- July 16, 2026: Jasper and Kira Pharmaceuticals finalize an all-stock merger agreement.
- July 17, 2026: The company secures $132 million in private financing, providing the liquidity required to move forward with a consolidated, multi-program pipeline.
The New Pipeline: Betting on the Complement System
By acquiring Kira, a startup launched in 2020 with backing from heavyweights like Foresite Capital, RA Capital Management, and Vivo Capital, Jasper gains access to advanced research in the "complement system." This network of proteins is a critical component of the body’s innate immune response. When functioning correctly, it clears pathogens and dead cells; however, dysregulation of this system is linked to various severe inflammatory and autoimmune diseases.
Key Assets Under the New Entity:
- KP-104: The centerpiece of the acquisition, KP-104 is a bifunctional molecule targeting the complement system. It is currently being investigated for paroxysmal nocturnal hemoglobinuria (PNH)—a rare, life-threatening blood disease—as well as rare kidney disorders such as IgA nephropathy (IgAN).
- KP-701: A bispecific drug designed to suppress B-cell function, representing a different approach to modulating the immune system compared to the complement-targeting assets.
- Briquilimab: Jasper’s legacy asset remains in the portfolio, albeit with a shifted focus. The company intends to pursue development for severe combined immunodeficiency (SCID), a rare and deadly immune disorder, and is preparing for a pre-approval submission meeting with the FDA.
Market Analysis and Clinical Potential
The integration of Kira’s assets has been met with cautious optimism from industry analysts. Matt Phipps, an analyst at William Blair, noted that recent Phase 2 data for KP-104 in PNH, presented at the American Society of Hematology, showed significant promise.
"Though the trial was small, the results suggest that KP-104 may possess ‘best-in-class’ potential," Phipps wrote in a recent research note. "There is even a possibility that its efficacy could exceed the benchmarks established by Novartis’s Fabhalta."
The competitive landscape for PNH and kidney-related inflammatory diseases is intense, with major players like Novartis and AstraZeneca (via its Alexion unit) holding significant market share. For Jasper to succeed, it must demonstrate not only clinical superiority but also the ability to execute large-scale trials—a capability that was severely strained during the company’s previous financial difficulties.
The Mirador Connection: Cleaning the Balance Sheet
As part of the consolidation process, the merger also involved a strategic divestiture. Kira entered into a licensing agreement with Mirador Therapeutics, an emerging leader in precision immunology.
Mirador, led by the executives who previously helmed Prometheus Biosciences (which was acquired by Merck in a multi-billion dollar deal), will take over two of Kira’s peripheral programs: KP-301, a long-acting antibody targeting the immune protein C5, and a related small-molecule program.
This deal is strategically sound for the new Jasper, providing an upfront payment of $12 million and potential milestone payments. By offloading these assets to Mirador, Jasper can focus its limited, albeit newly bolstered, resources on its lead programs, KP-104 and KP-701, while maintaining a lean operational structure.
Implications for Stakeholders
The merger is a double-edged sword for current shareholders. While the $132 million private offering provides necessary runway, it also results in substantial dilution of existing equity. However, in the context of the company’s previous near-zero market value, the deal represents a survival mechanism that avoids total liquidation.
For the biotech industry at large, the deal highlights a recurring theme in 2026: the "consolidation for survival" trend. As venture capital funding remains selective, struggling public companies are increasingly turning to private, science-heavy startups as a means of "reverse-merging" their way back into favor with Wall Street.
Future Milestones
The combined entity has a clear roadmap for the next 24 months:
- Late 2026/Early 2027: Anticipated reporting of Phase 2 data for KP-104 in kidney conditions.
- 2027: Preliminary data readouts for the bispecific program, KP-701.
- Ongoing: Consultations with the FDA regarding the regulatory pathway for briquilimab in SCID.
"The merger with Kira represents a total reset for Jasper," said a company spokesperson. "By combining our legacy assets with a proven, innovative pipeline, we are no longer just fighting to survive—we are building a platform capable of addressing significant unmet medical needs in immunology."
Whether this new, leaner, and more diverse Jasper can avoid the pitfalls that defined its recent past remains to be seen. The company’s success will now depend entirely on its ability to transition its promising complement-system inhibitors from the clinical trial phase to the regulatory finish line. For now, the infusion of $132 million and a refined pipeline provide the company with the most valuable commodity in biotechnology: time.
About the Author
